Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial

Fig. 2

Efficacy of TREND trial in EES. a pCR rate in primary tumors (ypT0/is) and axillary lymph nodes (ypN0) after neoadjuvant treatment, b Relationship between tpCR rate and CPS (left, CPS threshold =10; right, CPS threshold = 20), c Representative images of H&E staining in one pCR patient (no.12) and one non-pCR patient (no.10) before (left) and after (right) neoadjuvant treatment, d Waterfall plots of the best clinical response in EES, e Magnetic resonance imaging of representative clinical responses in two pCR patients (no.24, no.47) and two non-pCR patients (no.10, no.13) before and after neoadjuvant treatment. pCR pathological complete response, EES efficacy evaluable set, RECIST Response Evaluation Criteria in Solid Tumors, CR complete response, PR partial response, SD stable disease, PD progressive disease, CPS combined positive score, H&E hematoxylin and eosin. Data cutoff: June 30, 2023

Back to article page